Cetuximab added to capecitabine, oxaliplatin and bevacizumab in patients with previously untreated advanced colorectal carcinoma, a randomised phase III study.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 24 Jun 2020

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Bevacizumab (Primary) ; Cetuximab (Primary) ; Capecitabine; Oxaliplatin
Indications Carcinoma; Colorectal cancer
Focus Adverse reactions; Pharmacogenomic; Therapeutic Use
Acronyms CAIRO2

11 Jun 2020 Results of population pharmacodynamic modeling characterizing the changes in tumor size and CTC count, using patient data from this study published in the Clinical Cancer Research
11 Oct 2016 Results (n=182) analysing copy number alterations as predictive biomarkers to bevacizumab response, presented at the 41st European Society for Medical Oncology Congress.
01 Feb 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com